Breast Cancer | Specialty

Abemaciclib Improves PFS in Phase III MONARCH 3 Breast Cancer Trial

April 24th 2017

Adding abemaciclib to letrozole or anastrozole improved progression-free survival compared with either aromatase inhibitor alone in women with HR+/HER2-negative breast cancer enrolled in the phase III MONARCH 3 study, according to Eli Lilly and Company, the manufacturer of the CDK4/6 inhibitor.

Veliparib Falls Short in Phase III NSCLC, TNBC Trials

April 21st 2017

Veliparib failed to meet the primary endpoint in phase III non-small cell lung cancer and triple-negative breast cancer trials.

Expert Weighs in on Future of HER2-Positive Breast Cancer Treatment

April 20th 2017

C. Kent Osborne, MD, sheds light on the current and future treatment of HER2-positive breast cancer.

Future Directions for Metastatic Breast Cancer

April 19th 2017

Unmet Needs for Metastatic Breast Cancer

April 19th 2017

Patient Selection for Eribulin in Breast Cancer

April 19th 2017

Preclinical Observations on Eribulin for Breast Cancer

April 19th 2017

Dual MOA for Eribulin in Breast Cancer

April 19th 2017

Role of MOA When Choosing Breast Cancer Chemotherapy

April 19th 2017

Evolution of Chemotherapy for Metastatic Breast Cancer

April 19th 2017

Optimizing Chemotherapy for Metastatic Breast Cancer

April 19th 2017

Chemotherapy Use for Breast Cancer Subtypes

April 19th 2017

Chemotherapy for Metastatic Breast Cancer in 2017

April 19th 2017

Tripathy Offers Insights on Future of Breast Cancer From SABCS, ASCO

April 19th 2017

The 34th Annual Miami Breast Cancer Conference® featured a recap of significant research from the 2016 ASCO Annual Meeting and the 2016 San Antonio Breast Cancer Symposium.

Dr. Osborne Discusses Targeting the HER2 Pathway in Breast Cancer

April 18th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses targeting the HER2 pathway in breast cancer.

FDA Schedules ODAC Meeting for Neratinib in HER2+ Breast Cancer

April 18th 2017

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 24, 2017, to discuss a new drug application for neratinib as a treatment for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab, according to a statement from the developer of the TKI, Puma Biotechnology.

Dr. Janni on Challenges Facing the Treatment of HER2-Positive Breast Cancer

April 18th 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses challenges facing the treatment options for patients HER2-positive breast cancer.

Clinicians Must Evaluate Evidence Needed in Real-World Practice

April 17th 2017

Research on a scalp-cooling device to help patients with breast cancer avoid hair loss during chemotherapy illustrates this question: what level of evidence might individual clinicians require before they would suggest, recommend, or support the use of a particular approach in treating patients outside the realm of the mandates of governmental agencies or payers?

Expert Discusses Recommending Against Prophylactic Mastectomy

April 14th 2017

Steven J. Katz, MD, discusses his study of patient reaction to surgeon recommendations about contralateral prophylactic mastectomy for patients with breast cancer.

Dr. Disis on Immunotherapy in Breast Cancer

April 14th 2017

Mary L. (Nora) Disis, MD, professor of Medicine, Department of Medicine, University of Washington School of Medicine, discusses immunotherapy for patients with breast cancer.